Healthcare


 ASX 200 Sigma Healthcare Expansion Drives Market Focus

ASX 200 Sigma Healthcare Expansion Drives Market Focus

April 02, 2026 02:34 PM AEDT| By Sam

Sigma Healthcare reflects pharmacy distribution and retail activity, highlighting healthcare sector integration and supply chain operations within the ASX 200 market.

 These ASX 200 Healthcare Shares Are Turning Heads Today

These ASX 200 Healthcare Shares Are Turning Heads Today

April 02, 2026 12:42 PM AEDT| By Sam

ASX healthcare sector activity reflects medical innovation, operational frameworks, and sector participation across indices, highlighting the role of healthcare companies in broader market dynamics.

 Why ASX 200 Healthcare Shares Are Back in Focus After Sector Rout

Why ASX 200 Healthcare Shares Are Back in Focus After Sector Rout

April 02, 2026 12:11 PM AEDT| By Sam

ASX 200 healthcare shares face pressure amid sector decline, with select companies drawing attention as valuations reset.

 Can Healius (ASX:HLS) Redefine Diagnostics Growth?

Can Healius (ASX:HLS) Redefine Diagnostics Growth?

April 01, 2026 09:23 PM AEDT| By Sam

Healius explores growth in diagnostics through strong healthcare demand, digital innovation, and expanding service networks across Australia’s evolving medical landscape.

 Is This ASX 200 Healthcare Share Gearing Up for Growth?

Is This ASX 200 Healthcare Share Gearing Up for Growth?

April 01, 2026 05:10 PM AEDT| By Sam

Healthcare innovation continues to reshape market dynamics, with emerging companies gaining attention through clinical progress, global demand, and advanced treatment technologies within Australia’s evolving equities landscape.

 ASX 20: CSL Updates Market on Ongoing Share Buy-Back Strategy

ASX 20: CSL Updates Market on Ongoing Share Buy-Back Strategy

April 01, 2026 03:56 PM AEDT| By Sam

CSL continues its share buy-back program, highlighting strong capital management and reinforcing its position in the australian stock market.

 ASX 20 : CSL Buy-Back Update Signals Strategic Capital Move

ASX 20 : CSL Buy-Back Update Signals Strategic Capital Move

April 01, 2026 03:50 PM AEDT| By Sam

CSL’s ongoing share buy-back reflects strong capital management, supporting its position in the australian stock market and healthcare sector.

 Can Lumos (ASX:LDX) Accelerate US Diagnostics Expansion?

Can Lumos (ASX:LDX) Accelerate US Diagnostics Expansion?

April 01, 2026 03:47 PM AEDT| By Sam

Lumos Diagnostics strengthens its US presence with a major FebriDx order, supported by regulatory progress and rising demand for rapid point-of-care diagnostic solutions.

 Are All Ordinaries Trajan Shares Expanding Market Activity?

Are All Ordinaries Trajan Shares Expanding Market Activity?

March 31, 2026 05:25 PM AEDT| By Sam

Trajan Group seeks quotation for additional shares, highlighting capital structure developments and healthcare sector participation within the All Ordinaries index.

 ASX 200 CONNEQT Pulse Gains AARP Spotlight in Health Tech Push

ASX 200 CONNEQT Pulse Gains AARP Spotlight in Health Tech Push

March 31, 2026 03:58 PM AEDT| By Sam

CONNEQT Pulse gains recognition for advanced cardiovascular monitoring, strengthening its presence in the evolving healthcare technology space and highlighting the shift toward data-driven home health solutions.

 All Ordinaries HiTiQ Insider Gap Draws Attention

All Ordinaries HiTiQ Insider Gap Draws Attention

March 31, 2026 02:04 PM AEDT| By Sam

HiTiQ insider positioning reflects a gap from initial investment value, highlighting market dynamics and stakeholder alignment within the healthcare technology sector.

 Rhythm’s ColoSTAT Rollout Signals a New Commercial Phase

Rhythm’s ColoSTAT Rollout Signals a New Commercial Phase

March 31, 2026 11:29 AM AEDT| By Sam

Rhythm Biosciences has begun selling ColoSTAT in Australia, marking a major shift from development to commercial execution as the company expands access through an established pathology partnership.

 Is All Ordinaries Biotech PER Advancing Cancer Therapy Research?

Is All Ordinaries Biotech PER Advancing Cancer Therapy Research?

March 31, 2026 11:19 AM AEDT| By Sam

Percheron Therapeutics progresses oncology research with its HMBD therapy, highlighting regulatory engagement, biotech advancements, and presence within major ASX indices.

 Alterity Advances Toward Late-Stage Trial Pathway

Alterity Advances Toward Late-Stage Trial Pathway

March 30, 2026 07:31 PM AEDT| By Sam

Alterity Therapeutics progresses toward late-stage clinical development following regulatory alignment, reinforcing its strategy in neurological drug innovation and strengthening its pathway for future trial execution.

 Stock Market Spotlight: Breakthrough in Wound Care as (ASX:ARX) Advances Trial

Stock Market Spotlight: Breakthrough in Wound Care as (ASX:ARX) Advances Trial

March 30, 2026 07:14 PM AEDT| By Sam

Aroa Biosurgery advances wound care innovation with Symphony trial completion, showcasing improved healing outcomes and strengthening its clinical and commercial outlook in global healthcare markets.

 Market Watch ASX 100 Highlights Key Sector Activity

Market Watch ASX 100 Highlights Key Sector Activity

March 30, 2026 03:57 PM AEDT| By Sam

ASX 100 reflects sector-wide activity with CSL and key industries contributing to diversified market participation within the All Ordinaries framework.

 Blinklab ASX 300 Healthcare Operations and ASX Ordinaries Stocks

Blinklab ASX 300 Healthcare Operations and ASX Ordinaries Stocks

March 29, 2026 04:33 AM AEDT| By Sam

Blinklab healthcare operations focus on digital neurological screening systems and structured resource allocation within the ASX healthcare ecosystem and broader market framework.

 Telix Pharmaceuticals Update Sparks ASX Healthcare Momentum Shift

Telix Pharmaceuticals Update Sparks ASX Healthcare Momentum Shift

March 29, 2026 04:31 AM AEDT| By Sam

Telix Pharmaceuticals update highlights growing momentum in ASX healthcare sector as regulatory progress and innovation strengthen biotechnology outlook across Australian market landscape and investor attention expands steadily.

 Unlock PME Valuation Signals Ahead of ASX 200 Momentum

Unlock PME Valuation Signals Ahead of ASX 200 Momentum

March 29, 2026 04:27 AM AEDT| By Team Kalkine Media

PME reflects healthcare imaging strength, institutional integration, and digital transformation themes influencing Australian equities, structured valuation analysis, and long-term healthcare technology positioning across markets.

 Healthcare Innovator 4DMedical in ASX 300 Gains Attention

Healthcare Innovator 4DMedical in ASX 300 Gains Attention

March 29, 2026 04:24 AM AEDT| By Team Kalkine Media

4DMedical advances respiratory imaging technology while strengthening operations through a major capital raise, supporting global expansion and healthcare innovation within the ASX 300 landscape.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.